Glutaminyl cyclase as novel target for Parkinson’s disease therapy – Genetic and pharmacologic proof-of-principle
Parkinson’s disease is characterized, amongst others, by the deposition of a pathogenic protein in the brain. We recently discovered a particular variant of this protein that might be implicated in initiation and progression of the disease. However, the underlying molecular mechanisms of the formation of this protein variant are not yet deciphered. In a mouse model of Parkinson’s disease we would like to reveal the contribution of the potentially implicated enzyme using pharmacologic and genetic experiments.